Retina/Vitreous Panel - 2024 Financial Disclosures
Christina J. Flaxel, MD, Chair
No financial relationships to disclose
Steven T. Bailey, MD
BrightFocus Foundation, National Eye Institute, Research to Prevent Blindness - S
Stephen J. Kim, MD
No financial relationships to disclose
Jaclyn L. Kovach, MD
Genentech, Iveric Bio - C
Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. - L
Jennifer I. Lim, MD
Abbvie, Allergan, Inc., Aura Biosciences, Bausch + Lomb, Cognition Therapeutics, Eyenuk, Eyepoint, Genentech, Hoffman La Roche, Ltd., Iveric Bio, JAMA Network, Luxa, Novartis Pharma AG, Ophthea, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., RegenxBio, Santen Inc., Unity, Viridian - C
Adverum Biotechnologies, Aldeyra Therapeutics, Chengdu Kanghong Biotechnology, Genentech, Greybug, Janssen Pharmaceuticals, Inc., NGM, Regeneron Pharmaceuticals, Inc., RegenxBio, Spring Vision, Stealth Biotherapeutics - S
Gurunadh A. Vemulakonda, MD
Eyegenx, Lunate Health, Visgenx - PS
Gui-shang Ying, MD, PhD, Methodologist
Advarra, Atsena Therapeutics, Inc., Stoke Therapeutics, Ziemer Ophthalmic Systems AG - C
KEY:
C = Consultant/Advisor (consultant fee, paid advisory boards or fees for attending a meeting [for the past 1 year])
E = Employee (employed by a commercial entity)
L = Lecture Fees (lecture fees [honoraria], travel fees or reimbursement when speaking at the invitation of a commercial entity
PS = Private Equity/Stock Holder - Private Corporation
P = Patent/Royalties
S = Grant Support